Keep the person beside the peptide result.
A hormone rise, faster childhood growth and less deep abdominal fat answer different questions.
The family resemblance only gets us so far.
All three peptides copy growth hormone-releasing hormone, the brain’s message to the pituitary gland. That gland releases growth hormone, often shortened to GH. IGF-1 is a growth factor whose production GH helps drive. This review of the hormone family explains the shared biology.
That connection makes them worth reading together. Choosing a winner needs more: what changed, and who was it tested in? I keep those details together in the small comparison below. DAC, in the first row, is the attachment that helps CJC-1295 stay in the blood.
- CJC-1295 with DAC
- Healthy adults; a lasting GH and IGF-1 response.
- Sermorelin
- Prepubertal children with a GH shortage; faster average first-year growth, with no placebo group.
- Tesamorelin
- Adults with HIV and excess abdominal fat; less visceral fat over 26 weeks versus placebo.
Each row has a different kind of result. The names alone won’t tell you that.
What happened beyond the blood test?
CJC-1295 with DAC raised GH and IGF-1 in healthy adults. Those studies measured hormones and safety. They didn’t establish better sleep, fat loss or greater strength.
In the sermorelin childhood study, the first year brought faster average growth for children diagnosed with a GH shortage. There was no placebo group. The 26-week tesamorelin trial found less visceral fat, the fat around organs, among adults who had HIV and excess abdominal fat, using placebo for comparison. Neither result can be carried straight over to a healthy adult’s wellness goal.
Your own question might sit between these findings. It’s fine to leave that space open.
A treatment choice adds another layer.
What useful change is being sought? Did a study measure it in people with a similar condition? Those are questions I’d want to take into a care conversation. If the only answer is that a hormone level rose, the original question may still be waiting.
The products differ too: CJC-1295 has no FDA-approved medicine. Sermorelin’s former approvals ended, and compounded preparations made today have no FDA approval. Tesamorelin’s approved medicines address excess abdominal fat when adults have HIV-associated lipodystrophy. The prescribing page explains why those distinctions matter when moving from reading to a personal assessment.
A clinician can weigh your history and risks; a comparison page can help clarify the question.
Choose the page closest to your question.
There’s more detail on CJC-1295, sermorelin and tesamorelin. I’d keep the goal in plain words while reading. A study earns its usefulness by getting close to that goal.